Akero Therapeutics
BioTech/Drugs - South San Francisco, CA, US
Akero Therapeutics Employees
Brittany De Temple
director of clinical operations and program management
Akero Therapeutics Senior Management
Akero Therapeutics Details
Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), an engineered Fc-FGF21 fusion protein, is currently being evaluated in a Phase 2b clinical trial as a potential treatment for NASH. Akero is headquartered in South San Francisco.
Website:
akerotx.com
Employees:
20 - 49
HQ:
650-487-6488
Location:
South San Francisco, CA, US
Revenue:
2.5 - 5 Million
Akero Therapeutics Technologies
Email Providers
Mimecast
CMS
WP Engine
Fonts
Typekit
SSL Certificates
Media Temple SSL
Search Marketing
Adobe Marketing Cloud